[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR20000038352A - Drug containing catechin of green tea for prevention and treatment of cervical cancer - Google Patents

Drug containing catechin of green tea for prevention and treatment of cervical cancer Download PDF

Info

Publication number
KR20000038352A
KR20000038352A KR1019980053322A KR19980053322A KR20000038352A KR 20000038352 A KR20000038352 A KR 20000038352A KR 1019980053322 A KR1019980053322 A KR 1019980053322A KR 19980053322 A KR19980053322 A KR 19980053322A KR 20000038352 A KR20000038352 A KR 20000038352A
Authority
KR
South Korea
Prior art keywords
cervical cancer
treatment
cin
green tea
prevention
Prior art date
Application number
KR1019980053322A
Other languages
Korean (ko)
Other versions
KR100319973B1 (en
Inventor
하라 유키히꼬
안웅식
이인수
Original Assignee
이인수
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이인수 filed Critical 이인수
Priority to KR1019980053322A priority Critical patent/KR100319973B1/en
Priority to AU63715/99A priority patent/AU6371599A/en
Priority to PCT/KR1999/000651 priority patent/WO2000033832A1/en
Publication of KR20000038352A publication Critical patent/KR20000038352A/en
Application granted granted Critical
Publication of KR100319973B1 publication Critical patent/KR100319973B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PURPOSE: A drug component for prevention and treatment of cervical cancer containing catechin as an active substance is provided which enhances autolysis of cancer cell and has the chemical functions of anti-inflammation, anti-oxidation and anti-virus. CONSTITUTION: A green tea catechin is an active substance of drug for prevention and treatment of cervical cancer CIN I, II and III, originated from human papiloma virus(HPV), in the forms of gel, powder and/or capsule. The green tea catechin polyphenol group component can be taken for long term without side effects and shows excellent effect on treatment of malignant cervical cancer.

Description

녹차 카테킨을 유효성분으로하는 여성 자궁경부암 예방 또는 치료제Women's cervical cancer prevention or treatment with green tea catechin

본 발명은 여성 자궁경부암(CIN Ⅰ, Ⅱ 및 CIN Ⅲ) 예방 또는 치료제에 관한 것으로서 더욱 상세하게는 차 카텐킨(茶 catechin)을 유효성분으로 하는 사람유두종비루스(human papilloma virus; 이하 HPV라 함) 유래의 여성의 자궁경부암 CIN Ⅰ, Ⅱ 및 Ⅲ에 예방 또는 치료제에 관한 것이다.The present invention relates to a prophylactic or therapeutic agent for female cervical cancer (CIN I, II and CIN III), and more specifically, human papilloma virus (hereinafter referred to as HPV) containing tea catechin as an active ingredient. It relates to a prophylactic or therapeutic agent for cervical cancer CIN I, II and III of a woman of origin.

여성들의 자궁경부암 발생 병리과정에 있어서, 전이악성 장구암 단계에 이르기까지는 carcionma in Situ Ⅰ, Ⅱ 및 Ⅲ (CIN Ⅰ, Ⅱ 및 Ⅲ)의 단계과정을 경유하여 악성암세포들이 다른 조직에 전이하게 돤다. 이 자궁경부암의 원인은 현재 사람유두종비루스 HPV 18 또는 16으로 알려져 있다.In the pathogenesis of cervical cancer in women, malignant cancer cells have spread to other tissues through carcionma in Situ I, II and III (CIN I, II and III) until the stage of metastatic malignant cancer. The cause of cervical cancer is currently known as human papillomavirus HPV 18 or 16.

감염후 1∼6개월, 평균 3개월에서 임상증상이 발현하지만 통상 자각증상은 없다. 자궁경부암 CIN Ⅰ, Ⅱ 및 Ⅲ 병리적 단계의 조직 또는 경부 표면 조직을 채취하여 HPV 비루스의 DNA 정량분석 방법에 의하면 거의 100%의 검출률이 얻어진다. 비루스에는 주로 HPV 18이나 16이 검출되지만 자궁경부암인 경우에는 주로 HPV 16형이 검출이 되며 E6와 E7단백질이 자궁경부암 세포에 표현되는 것으로 보아 자궁경부암의 발생과정과 HPV 16형 비루스가 악성화에 관여하고 있을 가능성이 강력히 시사된다.Clinical symptoms are expressed at 1 to 6 months after infection and 3 months on average, but usually no subjective symptoms. Cervical cancer CIN I, II, and III pathological stages or cervical surface tissues were harvested and the DNA quantitative analysis of HPV viruses yielded nearly 100% detection rate. HPV 18 or 16 is detected mainly in viruses, but HPV type 16 is detected mainly in cervical cancer, and E 6 and E 7 proteins are expressed in cervical cancer cells. The possibility of being involved in is strongly suggested.

HPV유래의 치료법에는 외과적 절제, 전기부식 (electroacuterization), 동결치료, 레이저 등의 물리적 절제외에 항암치료제인 씨스프라틴(Cisplatin) 또는 카보프라틴(Carboplatin) 등으로 치료를 하고 있다. 그러나 외과적 치료법은 자궁 전체를 수술 제거함으로 아기를 원하는 여성들에 있어서는 이 방법은 고려할 수 없으며 또 항암제는 심각한 부작용과 치료후 불임의 가능성과 또 난자의 돌연변이로서 기형 또는 불임의 가능성이 높을 심각한 부작용의 우려가 있다. 그 때문에 임신을 하고 아기 출산을 원하는 여성들의 필요한 절대적인 치료법이 없는 것이 현상이다.HPV-derived treatments are treated with anti-cancer drugs such as cisplatin or carboplatin, in addition to physical resection such as surgical resection, electroacuterization, cryotherapy, and laser. Surgical treatment, however, cannot be considered in women who wish to have a baby by surgical removal of the entire uterus, and anticancer drugs have serious side effects, the possibility of post-treatment infertility, and severe side effects that may result in malformations or infertility as mutants of eggs. There is concern. That is why there is no absolute remedy for women who are pregnant and want to give birth to a baby.

CIN Ⅰ, Ⅱ 및 Ⅲ 발암단계에 진단이 규명됐을 때 치료하지 않으면 생명이 위험하다. 특히 CIN Ⅲ 암단계에서 항암치료의 반응이 없을 경우 수술제거를 신속히 하지 않으면 암전이가 일어나 생명이 위험하므로 안전성이 우수하고 더구나 간편한 치료방법의 출현이 강력히 요망되고 있다.If the diagnosis is established during the CIN I, II and III carcinogenic stages, life is at risk if not treated. In particular, if there is no response of chemotherapy at the CIN III cancer stage, if the surgery is not removed quickly, cancer metastasis occurs and the risk of life is excellent. Therefore, the emergence of an easy treatment method is strongly desired.

따라서, 본 발명의 목적은 HPV 유래의 자궁경부암 CIN Ⅰ, Ⅱ 및 Ⅲ단계의 치료에 있어서 환자에게 있어서 간편한 치료방법 예를 들면 환자자신의 손으로 자궁경부의 질에 삽입하여 도포할 수 있고 동시에 캡슐 경구투여로 단기간의 사용으로 충분한 치료효과를 얻을 수 있는 암예방제 또는 암치료제를 제공함에 있다. 본 발명의 다른 목적은 안정성이 우수한 치료방법을 제공함에 있다.Accordingly, an object of the present invention is to provide a convenient treatment method for patients in the treatment of HPV-derived cervical cancer CIN I, II and III, for example, by inserting into the vagina of the cervix by the patient's own hands and simultaneously encapsulating The present invention provides a cancer prevention agent or a cancer treatment agent that can be sufficiently treated by short-term use by oral administration. Another object of the present invention is to provide a therapeutic method having excellent stability.

본 발명자들은 부작용이 없고 장기간 사용해도 안전하고 더구나 현저한 치료효과를 나타내는 물질을 천연물 중에서 구하여 검토를 계속한 결과 일상 음용하고 있는 녹차의 성분인 카테킨류가 유효한 것을 발견하여 그러한 발견에 기초하여 본 발명을 완성하기에 이르렀다.The inventors of the present invention conducted a review of natural substances that have no side effects, are safe even for long-term use, and have a remarkable therapeutic effect, and found that catechins, which are components of green tea, which are routinely consumed, are effective. It was completed.

본 발명의 상기 목적은 녹차 카테킨을 주성분으로 하는 HPV 유래의 자궁경부암 CIN Ⅰ, Ⅱ 및 Ⅲ 치료제를 얻은 다음, 이를 자궁경부암 CIN Ⅰ, Ⅱ, Ⅲ 및 Ⅳ 단계에 있는 환자들에게 치료를 실시한 후 그 결과를 평가하므로써 달성하였다.The object of the present invention is to obtain cervical cancer CIN I, II and III therapeutic agents derived from HPV mainly composed of green tea catechins, and then treated the patients with cervical cancer CIN I, II, III and IV Achieved by evaluating the results.

이하, 본 발명의 구체적인 구성 및 작용을 설명한다.Hereinafter, the specific configuration and operation of the present invention.

본 발명에 사용되는 차 카테킨류는 하기 화학구조식 Ⅰ로 표시한 것이다.Tea catechins used in the present invention are represented by the following chemical structural formula (I).

(식중에서, R1은 H 또는 OH를 나타내고, R2는 H 또는Wherein R 1 represents H or OH and R 2 represents H or

를 나타낸다.) Is displayed.)

차 카테킨류(Camellia Sinensis)에는 구체적으로 에피카테킨(epicatechin), 에피카테킨갈레이트(epicatechingallate), 에피갈로카테킨갈레이트(epigallocatechingall ate), 갈로카테킨(gallocatechin)(이성체를 포함한다)등이 있다.Tea catechins (Camellia Sinensis) specifically include epicatechin (epicatechin), epicatechin gallate (epicatechingallate), epigallocatechin gallate (epigallocatechingall ate), gallocatechin (including isomers) and the like.

이들 차 카테킨류는 단독으로 또는 2종 이상을 적절히 조합해서 사용할 수가 있다. 이들 중에서 특히 유효한 것은 (-)-에피갈로카테킨갈레이트{(-)- Epigallo- catechin- 3-Gallate}를 함유하는 것이다. 예를 들면, 상품명 "폴리페논E" (미쓰이노린가부시끼가이샤제, 조성 : (-)에피갈로카테킨갈레이트 54.8%, (-)-에피카테킨 14.7%, (-)-에피카테킨갈레이트 6.7%, (-)-에피칼로카테킨 6.0%, (-)-갈로카테킨갈레이트 4.0%)등이 있으며 총 카테킨 함량은 86.2%이다.These tea catechins can be used individually or in combination of 2 or more types as appropriate. Particularly effective among these are those containing (-)-epigallocatechin gallate {(-)-Epigallocatecate- 3-Gallate}. For example, the product name "Polyphenone E" (Mitsinoringa Co., Ltd., Composition: (-) epigallocatechin gallate 54.8%, (-)-epicatechin 14.7%, (-)-epicatechin gallate 6.7%, (-)-Epicalcatechin 6.0%, (-)-gallocatechin gallate 4.0%) and the total catechin content is 86.2%.

본 발명의 자궁경부암 CIN Ⅰ,Ⅱ 및 Ⅲ 단계 예방 약제 및 치료제는, 예를 들면 크림상, 젤리상, 유액상 등의 도포제나 캡슐상등의 제제등의 형태로 사용하고 차 카테킨을 부형제, 중량제, 유화제, 분산제등과 배합해서 조제한다. 또한 도포제에 있어서의 기초재료로서는 와셀린(vacelline)이 아주 적당하다. 차 카테킨의 배합량은 도포제의 경우 5∼20중량%, 바람직하게는 12∼18중량%, 보다 바람직하게는 15중량%이다. 또, 캡슐제제의 경우 차 카테킨의 배합량은 100∼500㎎/캡슐이다.Cervical cancer CIN I, II and III prophylactic agents and therapeutic agents of the present invention, for example, in the form of a coating agent such as cream, jelly, emulsion, or capsules, etc. It is mixed with an emulsifier, a dispersing agent, and prepared. In addition, as a base material in a coating agent, vacelline is very suitable. The blending amount of the tea catechin is 5 to 20% by weight, preferably 12 to 18% by weight, more preferably 15% by weight in the case of the coating agent. In addition, in the case of capsule formulation, the compounding quantity of tea catechin is 100-500 mg / capsule.

도포제의 대표적인 사용 예를 나타내면 자궁경부 환부에 5∼20중량%의 차 카테킨을 포함하는 와셀린을 매주 2∼3회, 1∼3개월 계속해서 직접 도포한다. 또 제제의 대표적인 사용 예로서는 예를 들면, 자궁경부 환부의 경우 차카테킨을 1캡슐당 100∼500㎎를 포함한 것을 매일 2∼수회 경구복용과 더불어 매주 2∼3회씩 gel 도포를 1∼4개월간 병행 치료한다.Representative examples of the application of the coating agent are directly applied to the cervix affected area was Waselin containing 5 to 20% by weight of tea catechin 2 to 3 times a week for 1 to 3 months. In addition, as a representative example of the use of the preparation, for example, in the case of cervical lesions, the catechin containing 100-500 mg per capsule is administered twice or several times daily, and gel application is performed two to three times a week for 1 to 4 months. do.

하기 실시예들은 본 발명을 더욱 상세히 설명하지만 본 발명의 권리범위는 이들 실시예에만 한정되는 것이 아니며 다양한 변경의 실시가 가능하므로 이들 변경 실시예도 모두 포함함은 물론이다.The following examples illustrate the present invention in more detail, but the scope of the present invention is not limited only to these examples, and various modifications may be made, and therefore, all of these modification examples are included.

실시예 1Example 1

강남성모병원(서울시 강남구 소재) 산부인과에서 자궁경부암 진단 단계 CIN Ⅰ, Ⅱ, Ⅲ 및 Ⅳ 환자 22명에 본 발명품(Polyphenol E gel)를 자궁경부에 매주 2회씩 2∼4개월간 도포치료하고 치료반응이 없는 환자에게는 gel 도포를 계속하면서 Polyphenol E (200㎎/캡슐)를 매일 2회씩 (400㎎/일당) 복용하여 치료효과를 평가하였다. 최악성 경부암 환자 4명의 경우 8주간 자궁경부 도포 치료만으로도 3명이 완치되고 1명은 치료반응을 보이지 않았다 (75% 완치반응). 또 9명의 CIN Ⅰ 경부암 환자의 6∼8주후에 경부부의 도포 치료 결과를 보면 7명이 완치되고 2명은 완치되지 않았지만 치료반응이 좋은 것으로 나타났다(78%완치반응). 또 4명의 CIN Ⅱ 환자 중 2명이 경부부의 도포 치료로만 완치 되었고 1명은 도포치료와 경구투여를 병용하였을 때 완치되었다(75% 완치반응). 또 4명의 CIN Ⅲ 단계의 경부암 환자에 6∼12주간의 치료효과를 보면 1명은 자궁경부부의 도포 치료만으로 6주후에 완치 되였고 1명은 자궁경부부의 도포 치료 및 경구투여 (매일 2회씩 1회 200㎎ 캡슐)로 12주후에 완치, 그리고 1명은 치료반응은 있으나 10주에서 완치로 가는 호전을 보였고, 나머지 1명은 8주후에도 경구투여를 겸한 치료에도 불구하고 치료반응을 보이지 않아 계속 치료가 지속되고 있다.Diagnosis of cervical cancer at the Department of Obstetrics and Gynecology, Gangnam St. Mary's Hospital (Gangnam-gu, Seoul) The present invention (Polyphenol E gel) was applied to cervical cervix twice a week for 2 to 4 months. Patients who did not have gel application were treated with Polyphenol E (200mg / capsule) twice daily (400mg / day) to evaluate the therapeutic effect. Four patients with acute cervical cancer were cured by cervical application for 8 weeks and one patient did not respond (75% cure). In 6 to 8 weeks after 9 CIN I cervical cancer patients, 7 patients were cured and 2 were not cured but the response was good (78% curative response). Two of four CIN II patients were cured only by cervical application and one was cured by application of oral administration (75% cure). In addition, 6 to 12 weeks of treatment effect was observed in 4 patients with CIN III cervical cancer and 1 patient was cured after 6 weeks only by cervical application and 1 patient was treated with oral administration (200 twice a day) Mg capsules) cured after 12 weeks, and one patient had a curative response, but showed improvement from 10 weeks. The other one continued after 8 weeks because of no oral administration. have.

악성자궁경부암 CIN Ⅳ 단계 한 환자의 도포·복용 치료에서 좋은 치료반응을 보이고 있으나 8주 치료기간에 완치는 관찰되지 않고 있어 계속 치료가 지속되고 있다(표 1 및 표 2).Although malignant cervical cancer CIN IV stage shows a good treatment response in the application and intake treatment of one patient, no cures have been observed during the 8-week treatment period (Table 1 and Table 2).

본 발명품의 자궁경부암 치료 결과Cervical Cancer Treatment Results of the Invention NONO 환자번호Patient number 환자이름Patient name 나이age 병증상Symptoms 처리전HPV DNAHPV DNA before treatment 처리후HPVDNAHPVDNA after treatment 주중처리 계획Weekday Plan 기간(주)Period (week) 부작용Side Effect 치료결과Treatment result 1One 25-725-7 J.O KimJ.O Kim 3434 CCCC -- (-)(-) 22 88 -- 완전반응Complete response 22 3131 S.H.YS.H.Y 3939 CCCC 18.718.7 -- 22 88 -- 완전반응Complete response 33 3232 Y.J.YY.J.Y 2929 CCCC 1.951.95 -- 22 88 -- 완전반응Complete response 44 3030 M.O.CM.O.C 2828 CCCC 57.957.9 51.351.3 22 88 -- 저항성Resistance 55 2-12-1 Y.M.ChoiY.M.Choi 2929 CIN ⅠCIN Ⅰ 43.2143.21 1.231.23 22 88 -- 완전반응Complete response 66 3-13-1 Y.K.ChungY.K.Chung 3434 CIN ⅠCIN Ⅰ 17.017.0 1.231.23 22 1111 약간의 가려움증,1일간 발열Slight itching, fever for 1 day 완전반응Complete response 77 10-410-4 M.B.KimM.B.Kim 3030 CIN ⅠCIN Ⅰ 31.131.1 4.284.28 22 66 완전반응Complete response 88 88 Y.S.LY.S.L 3838 CIN ⅠCIN Ⅰ 38.938.9 -- 22 88 완전반응Complete response 99 1111 O.H.KO.H.K 3838 CIN ⅠCIN Ⅰ -- -- 22 88 완전반응Complete response 1010 1818 H.J.PH.J.P 2727 CIN ⅠCIN Ⅰ 2.82.8 -- 22 88 완전반응Complete response 1111 2929 H.J.YH.J.Y CIN ⅠCIN Ⅰ 7.17.1 -- 22 88 완전반응Complete response [주] 처리방법: Topical Application[Note] How to handle: Topical Application

본 발명품의 자궁경부암 치료 결과Cervical Cancer Treatment Results of the Invention NONO 환자번호Patient number 환자이름Patient name 나이age 병증상Symptoms 처리전HPV DNAHPV DNA before treatment 처리후HPVDNAHPVDNA after treatment 주중처리 계획Weekday Plan 기간(주)Period (week) 부작용Side Effect 치료결과Treatment result 1212 88 Y.S.LeeY.S.Lee 3838 CIN ICIN I 38.938.9 4.234.23 22 66 -- 부분반응Partial reaction 1313 23-623-6 Y.S.YimY.S.Yim 3333 CIN ICIN I 2.82.8 (-)(-) 22 88 -- 부분반응Partial reaction 1414 7-37-3 S.R.LeeS.R.Lee 2929 CIN ⅡCIN II 3.13.1 (-)(-) 22 88 -- 완전반응Complete response 1515 2626 Y.J.CY.J.C 4545 CIN ⅡCIN II 13.113.1 -- 22+poly E 200mg22 + poly E 200mg 88 -- 완전반응Complete response 1616 2828 S.O.CS.O.C 3838 CIN ⅡCIN II 9.29.2 -- 22 88 -- 완전반응Complete response 1717 2626 J.H.ChangJ.H.Chang 4545 CIN ⅡCIN II 13.113.1 (-)(-) 22+poly E 200mg22 + poly E 200mg 88 -- 부분반응Partial reaction 1818 15-515-5 C.N.KimC.N.Kim 4343 CIN ⅢCIN III 1.971.97 (-)(-) 22 66 -- 완전반응Complete response 1919 1919 M.Y.SungM.Y.Sung 3434 CIN ⅢCIN III 1.281.28 (-)(-) 22+poly E 200mg22 + poly E 200mg 1212 -- 완전반응Complete response 2020 2727 H.K.ChoiH.K.Choi 4040 CIN ⅢCIN III 23.323.3 (-)(-) 22 1010 -- 부분반응Partial reaction 2121 2424 M.O.YM.O.Y 3535 CIN ⅢCIN III 13.313.3 23.623.6 22+poly E 200mg22 + poly E 200mg 88 -- 저항성Resistance 2222 2121 J.O.LJ.O.L 4343 CIN ⅣCIN IV 4.34.3 -- 22 88 -- 부분반응Partial reaction [주] 처리방법: oral Application[Note] How to handle: oral Application

본 발명은 상기 임상 실험결과에서 명배한 바와 같이 녹차 카테킨 폴리페놀(Polyphenol)계 성분이 gel 형태나 분말을 캡슐로 한 형태에서도 암예방 치료의 효과뿐만 아니라 대부분의 악성 자궁경부암에서도 치료제로서의 효과가 있는 것으로 나타났다. 이 치료 효과는 사람유두종비루스 DNA가 완전히 제거되거나 유의한 감소가 치료반응에 비례하는 것을 볼 때 이들 Polyphenols (Camellia sinensis) 녹차 카테킨 성분들이 항바이루스, 항염증, 항산화성 또는 암세포 자연사의 촉진등 다양한 화학적 작용으로 치료 효과를 나타낸다고 판단되므로 본 발명은 생물의약 산업상 매우 유용한 발명인 것이다.The present invention, as noted in the above clinical trial results, green tea catechin polyphenol (Polyphenol) -based components in the form of a gel or powder capsules as well as the effect of cancer prevention treatment as well as a therapeutic agent in most malignant cervical cancer Appeared. This therapeutic effect is based on the complete elimination of human papillomavirus DNA or a significant decrease in proportion to the therapeutic response.These polyphenols (Camellia sinensis) green tea catechins have a variety of antiviral, anti-inflammatory, antioxidant or natural cell deaths. The present invention is very useful in the biopharmaceutical industry because it is judged to have a therapeutic effect by chemical action.

Claims (2)

녹차 카테킨(Catechin)을 유효성분으로하는 사람 유도종비루스 유래의 자궁경부암(CIN Ⅰ, Ⅱ 및 CIN Ⅲ) 예방 또는 치료제.A prophylactic or therapeutic agent for cervical cancer (CIN I, II, and CIN III) derived from human induced species virus containing green tea catechin as an active ingredient. 제 1항에 있어서, 상기 녹차 카테킨의 주성분이 (-)-에피갈로카테킨갈레이트임을 특징으로 하는 자궁경부암(CIN Ⅰ, Ⅱ, Ⅲ) 예방 또는 치료제.2. The cervical cancer (CIN I, II, III) prophylactic or therapeutic agent according to claim 1, wherein the main component of the green tea catechin is (-)-epigallocatechin gallate.
KR1019980053322A 1998-12-05 1998-12-05 Cervical epithelial tumor prophylaxis or treatment composition using green tea catechin as an active ingredient KR100319973B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1019980053322A KR100319973B1 (en) 1998-12-05 1998-12-05 Cervical epithelial tumor prophylaxis or treatment composition using green tea catechin as an active ingredient
AU63715/99A AU6371599A (en) 1998-12-05 1999-10-29 Chemical composition for treating cervical intraepithelial neoplasia i, ii, iii,iv and cervicitis
PCT/KR1999/000651 WO2000033832A1 (en) 1998-12-05 1999-10-29 Chemical composition for treating cervical intraepithelial neoplasia i, ii, iii, iv and cervicitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019980053322A KR100319973B1 (en) 1998-12-05 1998-12-05 Cervical epithelial tumor prophylaxis or treatment composition using green tea catechin as an active ingredient

Publications (2)

Publication Number Publication Date
KR20000038352A true KR20000038352A (en) 2000-07-05
KR100319973B1 KR100319973B1 (en) 2002-04-22

Family

ID=19561553

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980053322A KR100319973B1 (en) 1998-12-05 1998-12-05 Cervical epithelial tumor prophylaxis or treatment composition using green tea catechin as an active ingredient

Country Status (3)

Country Link
KR (1) KR100319973B1 (en)
AU (1) AU6371599A (en)
WO (1) WO2000033832A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100449228B1 (en) * 2002-03-19 2004-09-18 주식회사 태평양 EGCG derivatives, Preparation method thereof and cosmetic composition containing thereof
KR100801891B1 (en) * 2006-11-02 2008-02-12 한상진 Natural compositions for prevention or treatment of varginal infections

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10156794B4 (en) * 2001-11-19 2006-05-18 Medigene Ag Medicines for the treatment of warts
DE122009000073I1 (en) 2001-11-19 2010-03-25 Medigene Ag Lochhamer Strase 1 DRUGS FOR THE TREATMENT OF VIRAL SKIN AND TUMOR DISEASES
WO2005037300A1 (en) 2003-10-09 2005-04-28 Medigene Ag The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
US20050090564A1 (en) * 2003-10-28 2005-04-28 Wegener Paul T. Compositions and treatments of bacterial vaginosis
JP2008508252A (en) 2004-07-27 2008-03-21 ゲンプロファイラー エス．アール．エル． Catechin extracted from Chinese green tea or other vegetables, more precisely a mixture of polyphenols, with a chemical preventive effect for the prevention of prostate cancer pathogenesis and effective treatment of the overall symptoms of prostate hypertrophy (BPH)
US9145444B2 (en) 2007-11-02 2015-09-29 Ruprecht-Karls-Universität Heidelberg Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells
EP2179722A1 (en) * 2008-10-24 2010-04-28 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Topical formation for preventing sexual transmission of viral infection
EP2952182B1 (en) * 2014-06-04 2022-11-23 Universität Heidelberg Compounds and methods for increasing the immune response to papillomavirus
CN104922409A (en) * 2015-06-29 2015-09-23 孙霞 Traditional Chinese medicine for treating chronic cervicitis
CN104906449A (en) * 2015-06-30 2015-09-16 孙霞 Traditional Chinese medicine for treating cervicitis
CN107349197A (en) * 2017-07-13 2017-11-17 黄冈师范学院 A kind of application of catechin on the medicine for preparing treatment cutaneous papilloma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3213557B2 (en) * 1996-11-18 2001-10-02 三井農林株式会社 A remedy for condyloma acuminatum containing tea catechin as an active ingredient

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100449228B1 (en) * 2002-03-19 2004-09-18 주식회사 태평양 EGCG derivatives, Preparation method thereof and cosmetic composition containing thereof
KR100801891B1 (en) * 2006-11-02 2008-02-12 한상진 Natural compositions for prevention or treatment of varginal infections

Also Published As

Publication number Publication date
AU6371599A (en) 2000-06-26
KR100319973B1 (en) 2002-04-22
WO2000033832A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
KR100312252B1 (en) Composition for treating condyloma acuminata
JP3178844B2 (en) Use of flavanolignans for the manufacture of a medicament having antiproliferative activity in the uterus, ovaries and breast
CN101180036B (en) Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
US5968973A (en) Method for treating hyperplasia
US6197808B1 (en) Methods for treating hyperplasia
KR20000038352A (en) Drug containing catechin of green tea for prevention and treatment of cervical cancer
AU2016370126B2 (en) Medicine composition for treating leukemia and preparation method therefor
JP2017506241A (en) A composition useful for reducing peripheral inflammation and pain, comprising an extract of turmeric and josoba barrengiku
EP3074028B1 (en) Activity enhancing curcumin compositions and methods of use
WO2009109109A1 (en) Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors
NZ536360A (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
WO2006013420B1 (en) Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph)
JP4896354B2 (en) Composition comprising pollen extract for the treatment of hormone related diseases
RU2248212C2 (en) Preparation for treatment of bacterial vaginitis, method for its preparing and method for treatment of bacterial vaginitis
KR20190104118A (en) Pharmaceutical Composition for Treatment and Inhibiting Metastasis of Brain Tumor Comprising Acteoside
AU2018267649B2 (en) Method maintaining iron homeostasis with shogaols
CA3022493C (en) Method maintaining iron homeostasis with shogaols
CN108853007B (en) A kind of gel preparation and application thereof for treating functional uterine bleeding
JPH07316062A (en) Medicinal composition
WO2024076325A1 (en) Polyphenolic substance formulation with anti-cancerogenic effect
CN105031507A (en) Flos carthami tincture antibacterial liquid and preparation method thereof
CN118319989A (en) External traditional Chinese medicine composition for clearing heat, drying dampness, dispelling wind and relieving itching
WO2020152131A1 (en) Olive fruit extract suitable for reducing body-mass index and visceral fat in overweight subjects
JPS6229530A (en) Remedy for gill disease of eel

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
B701 Decision to grant
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee